Treatment of POEMS Syndrome with Castleman's Disease

Introduction to Treatment Approaches

• For patients with POEMS syndrome associated with Castleman's disease, radiation therapy is the definitive first-line treatment for localized disease, while systemic chemotherapy followed by autologous stem cell transplantation is recommended for disseminated disease, according to the American Society of Hematology 1, 2

Disease Stratification and Treatment Algorithm

• Radiation therapy is the treatment of choice for patients with solitary or limited sclerotic bone lesions, achieving 97% 4-year overall survival and 52% 4-year failure-free survival, as recommended by the National Comprehensive Cancer Network 1, 2
• Improvement occurs in 50-70% of patients treated with radiation alone, with the European Society for Medical Oncology noting the importance of this approach for localized disease 1, 2

Systemic Therapy Options

• Melphalan-dexamethasone achieves 81% hematologic response and 100% improvement in neuropathy in prospective trials, with the American College of Physicians recommending this regimen for disseminated disease 1, 2
• Lenalidomide-dexamethasone is preferred in patients with neuropathy due to lower neurotoxicity risk, as suggested by the European Hematology Association 1, 3

Autologous Stem Cell Transplantation

• Autologous stem cell transplantation should be offered to eligible patients after induction chemotherapy, achieving 100% clinical improvement in transplant-eligible patients, according to the American Society of Hematology 1, 2

Agents to Avoid

• Bortezomib-based regimens are not recommended as first-line due to induced neuropathy risk, despite high response rates, with the National Institute for Health and Care Excellence advising against their use 1, 2
• Thalidomide should be used cautiously given neurotoxicity concerns, though it shows particular efficacy in POEMS-CD, as noted by the European Society for Medical Oncology 1, 2

Expected Timeline and Monitoring

• Neurologic improvement significantly lags behind hematologic response, with maximum neurologic response expected after 2-3 years of successful therapy, according to the American Academy of Neurology 1, 2
• Serum VEGF levels should be monitored as a marker of disease activity and treatment response, with the International Society for Stem Cell Research recommending regular monitoring 1, 2, 4

Critical Pitfalls to Avoid

• Do not use radiation alone for disseminated disease, as it is not curative and systemic therapy is mandatory, with the American Society of Clinical Oncology advising against this approach 1, 2
• Do not underestimate the lag time between successful therapy and neurologic response—continue treatment even if immediate neurologic improvement is not apparent, as recommended by the European Society for Medical Oncology 1, 2